Extension Study of PRX-102 for up to 60 Months

Status Completed

Clinical Trial Summary

To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.

Clinical Trial Description

An open-label study to evaluate the ongoing safety, tolerability and efficacy parameters of PRX-102 in adult Fabry patients (≥18 years of age). Patients enrolled received 1.0 mg/kg of PRX-102 as an intravenous infusion every 2 weeks (+/- 3 days) for up to 60 months and no less than 36 months. ;

Study Design

Related Conditions & MeSH terms

Fabry Disease

Clinical Trial Details

NCT number	NCT01981720
Study type	Interventional
Source	Protalix
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 16, 2014
Completion date	November 9, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04893889` - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.	N/A
Completed	`NCT04455230` - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190	Phase 1/Phase 2
Completed	`NCT01218659` - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease	Phase 3
Completed	`NCT00304512` - A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease	Phase 2
Withdrawn	`NCT04189601` - Complement Activation in the Lysosomal Storage Disorders
Completed	`NCT03500094` - Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)	Phase 3
Withdrawn	`NCT04143958` - To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease	Phase 4
Recruiting	`NCT02994303` - Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy	N/A
Completed	`NCT01947634` - Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.	N/A
Recruiting	`NCT01695161` - Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.	N/A
Completed	`NCT01853852` - A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects	Phase 1
Completed	`NCT00701415` - A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms	Phase 3
Completed	`NCT00068107` - Dosing Study of Replagal in Patients With Fabry Disease	Phase 2
Completed	`NCT01997489` - Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.	Phase 4
Recruiting	`NCT06007768` - Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting	`NCT05698901` - Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Recruiting	`NCT03305250` - Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease	N/A
Terminated	`NCT00526071` - Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study	Phase 2
Active, not recruiting	`NCT03566017` - Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease	Phase 3
Recruiting	`NCT06065605` - Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease